SEC 01design + devREV 2023

Calidi Biotherapeutics

SEC 02

Overview

Website for a clinical-stage biotech company developing targeted immunotherapies for cancer. Needed to balance scientific credibility with accessibility for investors.

SEC 03

The Work

Designed and built the full site. Clean, authoritative visual language with generous whitespace and clear information hierarchy. Pipeline pages, investor content, team bios — all responsive and fast.

SEC 04

Engagement

After the 2023 redesign, Calidi kept DXD on a web-mastering and maintenance retainer for ongoing updates.

SEC 06

Tech

[ Webflow ][ Custom Design ][ UI/UX ][ CMS ]
SEC 07

Related work